Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Long-term Extension in Polyarticular JIA
NCT01667471Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2012
- Primary completion
- Aug 2013
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in juvenile idiopathic arthritis (JIA), sponsored by Roche. Started Jan 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT01667471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01667471.